Recommend Allopurinol Over Febuxostat for Most Chronic Gout Patients

Please see the February 2019 FDA advisory concerning the increased risk of death with Uloric (Febuxostat).

You'll hear about an advocacy group pushing for withdrawal of the gout med febuxostat (Uloric)...due to concerns it increases risk of death.

Patients with gout are already at elevated CV risk.

Early studies signaled a higher risk of CV events in patients on febuxostat compared to allopurinol...so FDA required a safety trial.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote